期刊文献+

选择性雌激素受体调节剂抗氧化作用的研究进展 被引量:3

Research advances of the antioxidative activities of selective estrogen receptor modulators
下载PDF
导出
摘要 选择性雌激素受体调节剂(selective estrogen receptor modulators,SERMs)是一类能与雌激素受体结合的类似雌激素的非甾体化合物,依据靶组织和激素的内环境不同而具有雌激素受体刺激或拮抗作用。SERMs主要通过清除氧自由基和抑制脂质过氧化,调节NO和一氧化氮合酶水平,抑制线粒体膜通透性转换,改善线粒体内游离脂肪酸的代谢,调控非基因转录活性通路等机制发挥抗氧化作用。 Selective estrogen receptor modulators (SERMs) is a class of estrogen-like non-steroid compounds that are able to bind to steroid hormone receptors .They can act as estrogen receptor agonist or antagonist depending on the target tissue and hormonal environment .Additionally , SERMs play an antioxidant role by scavenging oxygen free redicals , inhibiting lipid peroxidation , adjusting the level of NO and NOS , inhibiting mitochondrial permeability transition , improving the metabolism of free fatty acids in the mitochon-drial and regulating non-genomic transcription pathway .
出处 《医学研究生学报》 CAS 北大核心 2015年第1期94-97,共4页 Journal of Medical Postgraduates
基金 国家自然科学基金(31371520)
关键词 选择性雌激素受体调节剂 抗氧化 自由基 Selective estrogen receptor modulators Antioxidation Free radical
  • 相关文献

参考文献3

二级参考文献120

  • 1张志岷,廖丽萍,邹漳钰.ET-1与VEGF在OSAHS患者肺动脉高压形成中的意义[J].中国误诊学杂志,2009,9(3):561-562. 被引量:2
  • 2中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:843
  • 3Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008; 63: 163-81.
  • 4Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147: S269- 76.
  • 5Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab 2009; 94: 2284-9.
  • 6Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins IN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAM A 2006; 295: 2727 -41.
  • 7Sporn MB. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. Clin Cancer Res 2004; 10: 5313-5.
  • 8Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003; 14: 1383-90.
  • 9Yu B, Dietz BM, Dunlap T, Kastrati I, Lantvit DD, Overk CR, et al. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Mol Cancer Ther 2007; 6: 2418-28.
  • 10Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.

共引文献22

同被引文献39

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部